Review of the evidence for treatment of leiomyomata

Environmental Health Perspectives

Volumn 108, Issue SUPPL. 5, 2000, Pages 841-843

  Olive, David L ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Embolization; Evidence based; Hysterectomy; Laparoscopy; Leiomyoma; Medicine; Myolysis; Myomectomy; Supracervical

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; GONADORELIN AGONIST; MEDROXYPROGESTERONE ACETATE; SEX HORMONE;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER HORMONE THERAPY; CAUTERIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOTHERAPY; DATA ANALYSIS; DOSE RESPONSE; EVIDENCE BASED MEDICINE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LAPAROSCOPIC SURGERY; LASER SURGERY; LYSIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTICENTER STUDY; MYOMECTOMY; NEODYMIUM LASER; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SURGICAL APPROACH; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VASCULARIZATION; UTERINE ARTERY; UTERUS MYOMA;

EID: 0033674733     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.00108s5841     Document Type: Article

References (39)

1. Cytogenetic abnormalities in uterine leiomyomata
2. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues
3. Progesterone: A critical role in the pathogenesis of uterine myoma
4. What is evidence-based medicine?
5. Analysis of clinical fertility trials: A methodologic review
6. Quality of life assessment
7. Evidence-based medicine: Study design for evaluation and treatment
8. The Maine Women's Health Study. I: Outcomes of hysterectomy
9. A pragmatic randomized comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia
10. Randomized comparison of laparoscopy-assisted vaginal hysterectomy in an outpatient setting
11. A multicenter randomized comparison of laparoscopically assisted vaginal hysterectomy and abdominal hysterectomy in abdominal hysterectomy candidates
12. Supracervical hysterectomy: A time for reappraisal
13. Urethral closure function after total and subtotal hysterectomy measured by urethrocystometry
14. Bladder wall mechanics and micturition before and after subtotal and total hysterectomy
15. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids (Cochrane Review)
16. Intramyometrial vasopressin as a haemostatic agent during myomectomy
17. A randomized comparison of vasopressin and tourniquet as hemostatic agents during myomectomy
18. Adhesion formation and reproductive outcome after myomectomy and second look laparoscopy
19. Prevention of de-novo adhesion formation after laparoscopic myomectomy: A randomized trial to evaluate the effectiveness of an oxidized regenerated cellulose absorbable barrier
20. An expanded polytetrafluoroethylene barrier (Gore-Tex surgical membrane) reduces post-myomectomy adhesion formation
21. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): A blinded, prospective, randomized, multicenter clinical study. Adhesion Study Group
22. Risk of recurrence after myomectomy
23. The obstetrics outcome of patients with previous myomectomy or hysterotomy
24. Myomectomy. Surgical techniques and results in a series of 1150 cases
25. Abdominal myomectomy
26. Adhesion formation after laparoscopic myomectomy
27. Complications associated with the absorption of hysteroscopic fluid media
28. Safe and effective fluid management by automated gravitation during hysteroscopy
29. Operative hysteroscopy in physiologic distension media
30. Long term follow-up of hysteroscopic myomectomy assessed by survival analysis
31. Hysteroscopic myomectomy: Long-term effects on menstrual pattern and fertility
32. Laparoscopic coagulation of myoma (myolysis)
33. Experience with laparoscopic leiomyoma coagulation and concomitant operative hysteroscopy
34. Cryomyolysis, a new procedure for the conservative treatment of uterine fibroids
35. Uterine artery embolization for the treatment of uterine fibroids
36. Selective uterine artery embolization as primary treatment for symptomatic leiomyomata uteri
37. Fatal septicaemia after fibroid embolization
38. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin ″add-back″ regimens for women with leiomyomata uteri
39. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonist: The estrogen threshold hypothesis